Three-way Crossover Comparative Water-effect Bioavailability to Compare Ondansetron ODFS 8mg With and Without Water With Zofran ODT 8mg Without Water in 18 Healthy Participants Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01220167
Recruitment Status : Completed
First Posted : October 13, 2010
Last Update Posted : July 26, 2011
Information provided by:
Par Pharmaceutical, Inc.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : August 2008
  Actual Study Completion Date : August 2008

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 July 25, 2011
August 22, 2011
2 August 22, 2011
September 26, 2011
3 March 21, 2017
May 1, 2017
4 May 1, 2017
May 30, 2017
5 August 25, 2017
(Canceled - Date Unknown)
February 2, 2018